Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

99 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
Ishiguro H, Masuda N, Sato N, Higaki K, Morimoto T, Yanagita Y, Mizutani M, Ohtani S, Kaneko K, Fujisawa T, Takahashi M, Kadoya T, Matsunami N, Yamamoto Y, Ohno S, Takano T, Morita S, Tanaka-Mizuno S, Toi M. Ishiguro H, et al. Among authors: Matsunami N. Breast Cancer Res Treat. 2020 Apr;180(3):715-724. doi: 10.1007/s10549-020-05590-w. Epub 2020 Mar 13. Breast Cancer Res Treat. 2020. PMID: 32170634 Free PMC article.
Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.
Ueno T, Masuda N, Sato N, Ohtani S, Yamamura J, Matsunami N, Kashiwaba M, Takano T, Takahashi M, Kaneko K, Ohno S, Morita S, Toi M. Ueno T, et al. Among authors: Matsunami N. Jpn J Clin Oncol. 2020 Jan 24;50(1):3-11. doi: 10.1093/jjco/hyz119. Jpn J Clin Oncol. 2020. PMID: 31821506 Free PMC article. Clinical Trial.
Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
Iwasa T, Tsurutani J, Watanabe S, Kato R, Mizuno Y, Kojima Y, Takashima T, Matsunami N, Morimoto T, Yamamura J, Ohtani S, Tanabe Y, Yoshinami T, Takano T, Komoike Y, Nakagawa K. Iwasa T, et al. Among authors: Matsunami N. BMC Cancer. 2019 Oct 16;19(1):962. doi: 10.1186/s12885-019-6200-5. BMC Cancer. 2019. PMID: 31619197 Free PMC article. Clinical Trial.
Evaluation of the accuracy of urine analyzers in dogs and cats.
Mie K, Hayashi A, Nishida H, Okamoto M, Yasuda K, Nakata M, Fukatsu K, Matsunami N, Yamashita S, Ohashi F, Akiyoshi H. Mie K, et al. Among authors: Matsunami N. J Vet Med Sci. 2019 Dec 5;81(11):1671-1675. doi: 10.1292/jvms.18-0468. Epub 2019 Oct 11. J Vet Med Sci. 2019. PMID: 31611480 Free PMC article.
Graphene's Latest Cousin: Plumbene Epitaxial Growth on a "Nano WaterCube".
Yuhara J, He B, Matsunami N, Nakatake M, Le Lay G. Yuhara J, et al. Among authors: Matsunami N. Adv Mater. 2019 Jul;31(27):e1901017. doi: 10.1002/adma.201901017. Epub 2019 May 10. Adv Mater. 2019. PMID: 31074927
De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer.
Tanaka S, Matsunami N, Morishima H, Oda N, Takashima T, Noda S, Kashiwagi S, Tauchi Y, Asano Y, Kimura K, Fujioka H, Terasawa R, Kawaguchi K, Ikari A, Morimoto T, Michishita S, Kobayashi T, Sakane J, Nitta T, Sato N, Hokimoto N, Nishida Y, Iwamoto M. Tanaka S, et al. Among authors: Matsunami N. Cancer Chemother Pharmacol. 2019 Jun;83(6):1099-1104. doi: 10.1007/s00280-019-03836-z. Epub 2019 Apr 8. Cancer Chemother Pharmacol. 2019. PMID: 30963212 Clinical Trial.
A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
Kimura K, Iwamoto M, Tanaka S, Yamamoto D, Yoshidome K, Ogura H, Terasawa R, Matsunami N, Takahashi Y, Nitta T, Morimoto T, Fujioka H, Kawaguchi K, Uchiyama K. Kimura K, et al. Among authors: Matsunami N. Cancer Chemother Pharmacol. 2018 May;81(5):923-933. doi: 10.1007/s00280-018-3567-y. Epub 2018 Mar 28. Cancer Chemother Pharmacol. 2018. PMID: 29594360 Clinical Trial.
Germline but not somatic de novo mutations are common in human congenital diaphragmatic hernia.
Matsunami N, Shanmugam H, Baird L, Stevens J, Byrne JL, Barnhart DC, Rau C, Feldkamp ML, Yoder BA, Leppert MF, Yost HJ, Brunelli L. Matsunami N, et al. Birth Defects Res. 2018 Apr 17;110(7):610-617. doi: 10.1002/bdr2.1223. Epub 2018 Mar 23. Birth Defects Res. 2018. PMID: 29570242 Free PMC article.
Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC).
Nakayama T, Sagara Y, Takashima T, Matsunami N, Masuda N, Miyoshi Y, Taguchi T, Aono T, Ito T, Kagimura T, Noguchi S. Nakayama T, et al. Among authors: Matsunami N. Cancer Chemother Pharmacol. 2018 Apr;81(4):755-762. doi: 10.1007/s00280-018-3544-5. Epub 2018 Feb 21. Cancer Chemother Pharmacol. 2018. PMID: 29468454 Free PMC article. Clinical Trial.
Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).
Ohtani S, Nakayama T, Yoshinami T, Watanabe KI, Hara F, Sagara Y, Kawaguchi H, Higaki K, Matsunami N, Hasegawa Y, Takahashi M, Mizutani M, Morimoto T, Sato M, Itoh M, Morita S, Masuda N. Ohtani S, et al. Among authors: Matsunami N. Breast Cancer. 2018 Jul;25(4):438-446. doi: 10.1007/s12282-018-0843-y. Epub 2018 Feb 12. Breast Cancer. 2018. PMID: 29435730 Free PMC article. Clinical Trial.
99 results
Jump to page
Feedback